Ocugen, Inc. (OCGN)
| Market Cap | 1.38B |
| Revenue (ttm) | 42,620 |
| Net Income (ttm) | -37.50M |
| Shares Out | 186.30M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | 2.96 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $6.94 |
| Previous Close | $7.08 |
| Change ($) | -0.14 |
| Change (%) | -1.98% |
| Day's Open | 7.08 |
| Day's Range | 6.92 - 7.36 |
| Day's Volume | 10,251,547 |
| 52-Week Range | 0.25 - 18.77 |
New York, New York--(Newsfile Corp. - July 23, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) and certain of i...
BENSALEM, Pa., July 23, 2021 /PRNewswire/ -- Law Offices of Howard G.
Former penny stocks biotech analysts are bullish on right now. The post 3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120% appeared first on Penny Stocks to Buy, Picks, News and Info...
It would likely take until mid-2023 for the FDA to approve Covaxin. By that time, the shot could be obsolete.
New York, New York--(Newsfile Corp. - July 22, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Ocug...
New York, New York--(Newsfile Corp. - July 20, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that t...
New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 202...
Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the...
LOS ANGELES, July 20, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Oc...
The delta variant is lifting the tide of companies associated with COVID testing and prevention.
NEW YORK, July 16, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) and certain of its officers. Th...
New York, New York--(Newsfile Corp. - July 16, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGEN).Shar...
MALVERN, Pa., July 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness disease...
New York, New York--(Newsfile Corp. - July 16, 2021) - WHY: New York, N.Y., July 16, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ...
New York, New York--(Newsfile Corp. - July 16, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Ocugen, Inc. ("Ocugen") (NA...
There won't be a market for COVAXIN in the US as vaccination rates continue moving up. Without a successful US launch of COVAXIN, OCGN stock doesn't even warrant the price of a dollar.
New York, New York--(Newsfile Corp. - July 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that th...
We're taking a look at some of the lesser-known short-squeeze stocks popular with retail investors that should be on your radar. The post 9 Lesser-Known Short-Squeeze Stocks Popular With Retail Investor...
San Diego, California--(Newsfile Corp. - July 15, 2021) - The Ocugen, Inc. class action lawsuit charges Ocugen, Inc. (NASDAQ: OCGN) and certain of its top executives with violations of the Securities Ex...
Ocugen, Inc. (NASDAQ: OCGN) shares were advancing strongly Thursday after the biopharma issued a regulatory update. Pennsylvania-based Ocugen said it has initiated a rolling submission of its regulatory...
MALVERN, Pa., July 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness diseases ...
Toxic stocks are vulnerable to external shocks, burdened with high debt and bound to result in loss for investors over time. Discard such stocks from your portfolio right away to avoid losses.
SAN DIEGO--(BUSINESS WIRE)-- #OCGNstock--The suit alleges defendants issued false statements concerning Ocugen business and prospects, resulting in its stock trading at inflated prices.
The big jump resulted from the company's partnership with Bharat Biotech to commercialize COVID-19 vaccine Covaxin.
New York, New York--(Newsfile Corp. - July 13, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advise...
SAN DIEGO, July 12, 2021 /PRNewswire/ -- The Ocugen, Inc. class action lawsuit charges Ocugen, Inc. (NASDAQ: OCGN) and certain of its top executives with violations of the Securities Exchange Act of 193...
New York, New York--(Newsfile Corp. - July 12, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that th...
New York, New York--(Newsfile Corp. - July 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 202...
While the Delta variant Covid-19 strain threatens the population, OCGN stock investors can count on Ocugen to advance its vaccine candidate. The post Ocugen's Recent Vaccine Efficacy Results Should Have...
NEW YORK, July 10, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10,...
Investors may be getting concerned about how long it may take for COVID-19 vaccine Covaxin to get approved.
Los Angeles, California--(Newsfile Corp. - July 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" ...
Stock markets moved slightly higher despite general worries.
BENSALEM, Pa., July 7, 2021 /PRNewswire/ --Law Offices of Howard G.
Los Angeles, California--(Newsfile Corp. - July 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen"...
Phase 3 data on Covaxin wasn't outstanding, and there are indications that demand for additional vaccines in the U.S. and Canada will be low for some time. OCGN remains a good stock to short.
These seven meme stocks to buy could be good picks for July as investor interest in these high-risk, high-return plays continues to grow. The post 7 Meme Stocks to Buy for Their ‘To-the-Moon' Potential ...
Ocugen Inc. (NASDAQ: OCGN) shares traded higher Tuesday after the company announced that its coronavirus vaccine co-development partner Bharat Biotech reported Phase 3 results demonstrating 77.8% protec...
OCGN stock has been counted out of the vaccine race many times, but there is plenty of room for optimism moving forward. The post 3 Reasons Ocugen Stock Should Maintain Its Upward Trajectory appeared fi...
Los Angeles, California--(Newsfile Corp. - July 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" ...
Ocugen's Indian vaccine development partner reported better-than-expected results from its local Covid-19 vaccine trials. OCGN stock has been on a roller-coaster ride on every Covaxin rumor and news item.
Armed with new data from its development partner Bharat Biotech, Ocugen Inc (NASDAQ: OCGN) plans to press ahead with plans to file for approval of their COVID-19 vaccine, Covaxin, in the U.S. and Canada...
While the contrarian bullish argument for OCGN stock has picked up considerable chatter, this is an extremely risky trade. The post Don't Play the Ocugen Stock Short Squeeze Before You Read This Warning!
Ocugen was a penny stock is up 180% for the year. But all good things must come to an end.
New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advised ...
New York, New York--(Newsfile Corp. - July 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Ocug...
Los Angeles, California--(Newsfile Corp. - July 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" ...
It may equal some coronavirus vaccine revenue ahead.
MALVERN, Pa., and HYDERABAD, India, July 02, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to ...
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development st... [Read more...]
| Industry Biotechnology | |
| CEO Shankar Musunuri | Employees 15 |
| Stock Exchange NASDAQ | Ticker Symbol OCGN |
Analyst Forecasts
According to 4 analysts, the average rating for Ocugen stock is "Buy." The 12-month stock price forecast is 5.38, which is a decrease of -22.48% from the latest price.